Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
These 2 companies are teaming up to offer insurance for space debris strikes on satellites - 2Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey
- 3Kansas school officials report high student illness, dismiss early
- 4Robert Pattinson claims he's a pathological liar. What 'The Drama' star has said about his 'shtick'
- 5The most effective method to Begin Your Excursion in Gold Venture
- Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- Etymological Investigation Disclosed: A Survey of \Dominating New Tongues\ Language Learning Application
- 'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law
- Doctors looking into hormone therapy as a way to ward off dementia in women
- Eating Brie, Gouda, cheddar may lower dementia risk, new study says
- The Best Portable Applications for Psychological wellness and Prosperity
- Cyber Monday 2025 streaming deal: Get $42 off six months of Apple TV
- These are the Fastest Italian Sports Cars
- Former 'Bachelorette' welcomes 1st baby via emergency c-section
